ImmuneWatch signs licence agreement with UAntwerp and UZA and officially becomes a university spin-off company
There’s a new start-up in the Flemish field of biotechnology. The University of Antwerp and Antwerp University Hospital announce their new spin-off: ImmuneWatch. The company builds digital technology based on artificial intelligence to monitor and predict immune responses. This technology should make the development of vaccines, diagnostics and immunotherapy more efficient. The seed for the […]
Professor Kris Laukens (University of Antwerp / ImmuneWatch) receives an award from the AstraZeneca Foundation, after selection by independent juries of the FWO (Scientific Research Fund) and the FNRS (Fonds de la Recherche Scientifique). His team develops a digital map of the adaptive immune system, which is the basis of the ImmuneWatch technology. Article continues […]
ImmuneWatch invited to present at the state of the union of Flanders.bio and VIB during the Young Company Pitches
On the 18th of May 2022, VIB and flanders.bio are organising the 8th edition of their State of the Union. This event is part of the Knowledge for Growth which connects the Belgian life sciences community. During the State of the Union, VIB and flanders.bio take a moment to announce new developments and initiatives in the Flemish […]
At ImmuneWatch, we embrace machine learning and (interpretable) deep learning in immunology. Based on T-cell sequencing data, we specialise in predicting what epitope a specific T-cell receptor will bind to. This information will lead to clinical actionable insights, because these epitopes are linked to the pathogen from which they are derived. And even further, the […]
Thinking about interrogating the T-cell response using single-cell sequencing technologies? Good idea! The combination of transcriptomic- and repertoire information can provide novel insight into the functional character of T cell immunity and provides paired αβ TCR repertoire data. Want to learn more? Have a look at this brand new manuscript co-authored by some of the […]
“Immunosequencing of T cells, combined with machine learning techniques, may enable scientists to predict which patients will have early, strong protection against hepatitis B infection following vaccination.” That is the conclusion of a study performed and co-ordinated by the academic (University of Antwerp) scientific advisors and co-founders of ImmuneWatch. The study is published in the […]
ImmuneWatch releases white paper evaluating the effect of mutations gathered in the SARS-COV-2 Omicron variant on T cell immunity
Omicron, the latest SARS-COV-2 variant of concern is characterized by a large number of mutations. In our first white paper, we evaluate the effect of these mutations on T-cell immunity by applying a T-cell receptor (TCR)/epitope interaction model.
We are happy to announce that we have been selected to pitch our startup at “Immunity for Health 2021” in Ghent on October 14, 2021.
Our CTO, Pieter Meysman is invited by Lexogen to give a webinar on the topic of: “Why are Vaccines Effective in Some Individuals but Not in Others?” Abstract Transcriptomic profiling has been used to identify key immunological determinants that underpin vaccine response in individuals. Most critically, it is now known that the state of the […]
ImmuneWatch is featured on Z-HealthCare. Watch the video here: